Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Turkish Decree Places New Caps On Drug Price Increases

Executive Summary

In order to help curb the drugs bill, the Turkish Social Security Institution has decided to restrict the level of price increases that can be made on pharmaceutical products when the prices of those products are increased in reference or non-reference countries.

You may also be interested in...

Localization Barriers To Trade In Medicines And Health Care Products: The Tricky Business Of Balancing Competing Interests

There is a clear tension at a global level between the need for the international movement of pharmaceutical products and the need for access to affordable medicines to support a sustainable health care system. Lincoln Tsang examines the global environment and suggests it is something that the British medicines and health care products industries will need to bear in mind when considering the prospect of the UK leaving the EU under WTO terms, as some are advocating.

Inadequate And Counterproductive: Industry Criticizes Turkey’s Local Drug Production Policy

The general secretary of Turkey’s Association of Research based Pharmaceutical Companies (AIFD), Umit Dereli, tells the Pink Sheet why he thinks the government’s policy on local medicines production is wrong in terms of its scope, goal, and method.

How Might Turkey Contain Its Rising Health Care Bill?

As Turkey’s government discloses health care and drug budget plans for 2017, it is becoming clear that controlling the rise in national costs while meeting needs will remain central to policies, prompting the consideration of a variety of approaches.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts